Publications:  Prof James Lindsay

Din S, Kent A, Pollok RC, Meade S, Kennedy NA, Arnott I, Mark Beattie R, Chua F et al.(2020). Adaptations to the British Society of Gastroenterology guidelines on the management of acute severe UC in the context of the COVID-19 pandemic: A RAND appropriateness panel. Gut vol. 69, (10) 1769-1777.

Ball J, Clear A, Aries J, Charrot S, Besley C, Mee M, Stagg A, Lindsay J et al.(2020). Retinoic acid-responsive CD8 effector T-cells are selectively increased in IL-23-rich tissue in gastrointestinal GvHD. Blood

Sandall AM, Cox SR, Lindsay JO, Gewirtz AT, Chassaing B, Rossi M, Whelan K(2020). Emulsifiers impact colonic length in mice and emulsifier restriction is feasible in people with Crohn’s disease. Nutrients vol. 12, (9) 1-20.

Kennedy NA, Hansen R, Younge L, Mawdsley J, Beattie RM, Din S, Lamb CA, Smith PJ et al.(2020). Organisational changes and challenges for inflammatory bowel disease services in the UK during the COVID-19 pandemic. Frontline Gastroenterology vol. 11, (5) 343-350.

Powell N, Ibraheim H, Raine T, Speight RA, Papa S, Brain O, Green M, Samaan MA et al.(2020). British Society of Gastroenterology endorsed guidance for the management of immune checkpoint inhibitor-induced enterocolitis. The Lancet Gastroenterology and Hepatology vol. 5, (7) 679-697.

Gadhok R, Gordon H, Sebepos-Rogers G, Baillie S, Akbar S, Abbott JE, Michael E, Ahmad OF et al.(2020). UK Patients of Bangladeshi Descent with Crohn’s Disease Respond Less Well to TNF Antagonists Than Caucasian Patients. Digestive Diseases and Sciences vol. 65, (6) 1790-1799.

Kennedy NA, Jones GR, Lamb CA, Appleby R, Arnott I, Beattie RM, Bloom S, Brooks AJ et al.(2020). British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic. Gut

Levine A, Rhodes JM, Lindsay JO, Abreu MT, Kamm MA, Gibson PR, Gasche C, Silverberg MS et al.(2020). Dietary Guidance From the International Organization for the Study of Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology vol. 18, (6) 1381-1392.

Sands BE, Armuzzi A, Marshall JK, Lindsay JO, Sandborn WJ, Danese S, Panés J, Bressler B et al.(2020). Letter: corticosteroid use alongside tofacitinib in OCTAVE Open. Authors' reply. Alimentary Pharmacology and Therapeutics vol. 51, (10) 997-998.

Curtius K, Kabir M, Al Bakir I, Choi CHR, Hartono JL, Johnson MJ, East JE, Lindsay J et al. (2020). MULTI-CENTRE VALIDATION OF RISK STRATIFICATION FOR COLITIS PATIENTS WITH LOW GRADE DYSPLASIA USING UC-CARE: A PREDICTIVE CLINICAL DECISION SUPPORT TOOL. GASTROENTEROLOGY. vol. 158, S1172-S1173.

Curtius K, Kabir M, Bakir IA, Choi CHR, Hartono JL, Johnson MJ, East JE, Lindsay J et al.(2020). Tu1814 MULTI-CENTRE VALIDATION OF RISK STRATIFICATION FOR COLITIS PATIENTS WITH LOW GRADE DYSPLASIA USING UC-CARE: A PREDICTIVE CLINICAL DECISION SUPPORT TOOL. Gastroenterology vol. 158, (6)

Staudacher H, Scholz M, Lomer M, Ralph F, Irving P, Lindsay J, Fava F, Tuohy K et al. (2020). Diet and the microbiota in irritable bowel syndrome: Baseline associations and the impact of dietary intervention. NEUROGASTROENTEROLOGY AND MOTILITY. vol. 32,

Czuber-Dochan W, Morgan M, Hughes LD, Lomer MCE, Lindsay JO, Whelan K(2020). Perceptions and psychosocial impact of food, nutrition, eating and drinking in people with inflammatory bowel disease: a qualitative investigation of food-related quality of life. Journal of Human Nutrition and Dietetics vol. 33, (1) 115-127.

Sands BE, Moss AC, Armuzzi A, Marshall JK, Lindsay JO, Sandborn WJ, Danese S, Zeroncio M et al. (2020). Efficacy and safety of escalation to tofacitinib 10 mg BID for patients with UC following loss of response on 5 mg BID maintenance therapy: Results from OCTAVE open-label, long-term extension study. JOURNAL OF CROHNS & COLITIS. vol. 14, S110-S111.

Sands BE, Armuzzi A, Marshall JK, Lindsay JO, Sandborn WJ, Danese S, Panés J, Bressler B et al.(2020). Efficacy and safety of tofacitinib dose de-escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open. Alimentary Pharmacology and Therapeutics vol. 51, (2) 271-280.

Sandall A, Cox S, Lindsay JO, Rossi M, Whelan K(2020). Food additive emulsifier restriction is feasible in people with Crohn's disease. Proceedings of the Nutrition Society vol. 79, (OCE1)

Gordon H, Murray J, Tailor F, Goh SA, Lindsay JO (2020). Frequent disease relapse after withdrawal of infliximab in IBD patients with sustained remission. JOURNAL OF CROHNS & COLITIS. vol. 14, S471-S471.

Kabir M, Curtius K, Al-Bakir I, Hartono J, Johnson M, East JE, Lindsay JO, Vega R et al. (2020). Low-grade dysplasia prognosis and predictive factors for advanced neoplasia progression in the 21st century: A large multi-centre retrospective cohort study. JOURNAL OF CROHNS & COLITIS. vol. 14, S078-S079.

Wilson B, Rossi M, Eyice O, Lomer MC, Irving PM, Lindsay JO, Whelan K (2020). Prebiotic β-galacto-oligosaccharide impact on clinical, inflammatory and microbiota outcomes in active ulcerative colitis: An open-label study. Proceedings of the Nutrition Society. Conference: Nutrition Society

Gadhok R, Fragkos K, Honap S, Hassan J, Whiteley L, Ibarra A, Burgess N, Vega R et al. (2020). Ustekinumab: Medium-term outcomes from a UK multicentre real-world cohort. JOURNAL OF CROHNS & COLITIS. vol. 14, S439-S440.

Sazonovs A, Kennedy NA, Moutsianas L, Heap GA, Rice DL, Reppell M, Bewshea CM, Chanchlani N et al.(2019). HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn's Disease. Gastroenterology vol. 158, (1) 189-199.

Cox SR, Lindsay JO, Fromentin S, Stagg AJ, McCarthy NE, Galleron N, Ibraim SB, Roume H et al.(2019). Effects of Low-FODMAP Diet on Symptoms, Fecal Microbiome, and Markers of Inflammation in Patients With Quiescent Inflammatory Bowel Disease in a Randomized Trial. Gastroenterology

D'Haens GR, Lindsay JO, Loftus EV, Zhou W, Cataldi F, Xie W, Pugatch D, Panaccione R (2019). 678 Efficacy of Upadacitinib as an Induction Therapy in Severe and Refractory Ulcerative Colitis: Sub-Group Analysis of the Phase 2b Study U-ACHIEVE. The American Journal of Gastroenterology. vol. 114, s399-s399.

Baker AM, Cross W, Curtius K, Al Bakir I, Choi CHR, Davis HL, Temko D, Biswas S et al.(2019). Evolutionary history of human colitis-associated colorectal cancer. Gut vol. 68, (6) 985-995.

Gadhok R, Rao R, Honap S, Samaan M, Harpham-Lockyer L, Kwok H, Whitley L, Ibarra A et al. (2019). PTH-084 Ustekinumab: Early experience and medium-term outcomes from a UK multi-centre real-world cohort. Gut. vol. 68,

D¿Haens GRAM, Lindsay JO, Panaccione R, Schreiber S(2019). Ulcerative Colitis: Shifting Sands. Drugs in R and D vol. 19, (2) 227-234.

Snowden JA, Hawkey C, Hind D, Swaby L, Mellor K, Emsley R, Mandefield L, Lee E et al.(2019). Autologous stem cell transplantation in refractory Crohn's disease - Low intensity therapy evaluation (ASTIClite): Study protocols for a multicentre, randomised controlled trial and observational follow up study. BMC Gastroenterology vol. 19, (1)

Kennedy NA, Heap GA, Green HD, Hamilton B, Bewshea C, Walker GJ, Thomas A, Nice R et al.(2019). Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study. The Lancet Gastroenterology and Hepatology vol. 4, (5) 341-353.

Honap S, Gadhok R, Rao R, Samaan MA, Harpham-Lockyer L, Kwok H, Whitley L, Ibarra A et al. (2019). USTEKINUMAB: EARLY EXPERIENCE AND MEDIUM-TERM OUTCOMES FROM A UK MULTI-CENTRE REAL-WORLD COHORT. GASTROENTEROLOGY. vol. 156, S885-S886.

Lewis A, Nijhuis A, Berti G, Felice C, Jeffrey R, Iqbal S, Pomeranc AB, Aldelemi S et al. (2019). Drugs that modulate histone acetylation disrupt TGF-beta-signalling and reduce collagen I expression in models of stricturing Crohn's disease. JOURNAL OF CROHNS & COLITIS. vol. 13, S38-S38.

Walker GJ, Harrison JW, Heap GA, Voskuil MD, Andersen V, Anderson CA, Ananthakrishnan AN, Barrett JC et al.(2019). Association of Genetic Variants in NUDT15 With Thiopurine-Induced Myelosuppression in Patients With Inflammatory Bowel Disease. JAMA vol. 321, (8) 773-785.

Sandborn WJ, Schreiber S, Lee SD, Lindsay JO, Hebuterne X, Zhou W, Cataldi F, Lacerda AP et al. (2019). OP14 Improved endoscopic outcomes and mucosal healing of upadacitinib as an induction therapy in adults with moderately to severely active ulcerative colitis: data from the U-ACHIEVE study. Journal of Crohn's and Colitis. vol. 13, s009-s009.

Lewis A, Jeffrey R, Kumagai T, Hawkey CJ, Clark MM, Allez M, Satsangi J, Rogler G et al. (2019). OP20 Mucosal micoRNA profiles predict response to autologous stem-cell transplantation in Crohn’s disease. Journal of Crohn's and Colitis. vol. 13, s014-s014.

Harrow P, Datta R, Stagg A, Lindsay JO (2019). P012 IL22 expression in intestinal immune cells is not augmented by AHR activation in health or Crohn’s disease. Journal of Crohn's and Colitis. vol. 13, s092-s092.

Hornsby E, Peiris M, Peiris M, King HW, Wing ES, Lindsay JO, Blackshaw LA, Stagg AJ (2019). P016 Constitutive activity of the cation channel TRPM8 regulates monocyte to macrophage transition in humans to control intestinal inflammation. Journal of Crohn's and Colitis. vol. 13, s094-s094.

Lewis A, Nijhuis A, Berti G, Bishop CL, Feakins R, Lindsay JO, Silver A (2019). P035 Pharmacological inhibition of the canonical WNT signalling pathway represents a potential novel therapy for fibrosis in Crohn’s disease. Journal of Crohn's and Colitis. vol. 13, s103-s104.

Hoti I, McCarthy N, Giles E, Ayada I, Harrow P, Gordon H, Stagg A, Lindsay J (2019). P092 Circulating classical monocytes and intestinal macrophages exhibit reduced response to IL-10 in IBD. Journal of Crohn's and Colitis. vol. 13, s131-s132.

Gadhok R, Rao R, Honap S, Samaan M, Harpham-Lockyer L, Kwok H, Whitley L, Ibarra A et al. (2019). P318 Ustekinumab: early experience and medium-term outcomes from a UK multi-centre real-world cohort. Journal of Crohn's and Colitis. vol. 13, s260-s260.

Rao R, Gadhok R, Whitley L, Burgess N, Amon P, Naik S, Lindsay J, McCartney S et al. (2019). P616 Ustekinumab for refractory paediatric Crohn’s disease: experience from two UK tertiary referral centres. Journal of Crohn's and Colitis. vol. 13, s424-s425.

Panés J, Vermeire S, Lindsay JO, Sands BE, Su C, Friedman G, Zhang H, Yarlas A et al.(2019). Erratum: Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance Studies (Journal of Crohn's & colitis (2018) 12 2 (145-156)). Journal of Crohn's & colitis vol. 13, (1) 139-140.

Kok K, Ibarra A, Lindsay J(2019). New Therapeutic Strategies. Inflammatory Bowel Disease Nursing Manual,

Mehta SJ, Lewis A, Nijhuis A, Jeffery R, Biancheri P, Di Sabatino A, Feakins R, Silver A et al.(2018). Epithelial down-regulation of the miR-200 family in fibrostenosing Crohn's disease is associated with features of epithelial to mesenchymal transition. J Cell Mol Med vol. 22, (11) 5617-5628.

Snowden JA, Sharrack B, Akil M, Kiely DG, Lobo A, Kazmi M, Muraro PA, Lindsay JO(2018). Autologous haematopoietic stem cell transplantation (aHSCT) for severe resistant autoimmune and inflammatory diseases - A guide for the generalist. Clinical Medicine, Journal of the Royal College of Physicians of London vol. 18, (4) 329-334.

Alexander T, Farge D, Badoglio M, Lindsay JO, Muraro PA, Snowden JA(2018). Hematopoietic stem cell therapy for autoimmune diseases – Clinical experience and mechanisms. Journal of Autoimmunity vol. 92, 35-46.

Samaan MA, Shen B, Mosli MH, Zou G, Sandborn WJ, Shackelton LM, Nelson S, Stitt L et al.(2018). Reliability among central readers in the evaluation of endoscopic disease activity in pouchitis. Gastrointestinal Endoscopy vol. 88, (2) 360-369.e2.

Cox S, Stagg A, Fromentin S, Ehrlich D, McCarthy N, Galleron N, Levenez F, Lomer M et al. (2018). ADWE-09 Low fodmap diet improves functional-like gastrointestinal symptoms but reduces bifidobacteria in quiescent inflammatory bowel disease. Gut. vol. 67,

Czuber-Dochan W, Morgan M, Lomer M, Lindsay J, Robert G, Whelan K (2018). MANAGING ISSUES WITH FOOD-RELATED QUALITY OF LIFE IN INFLAMMATORY BOWEL DISEASE - A QUALITATIVE STUDY. GUT. vol. 67, A162-A162.

Yarlas A, Rubin DT, Panés J, Lindsay JO, Vermeire S, Bayliss M, Cappelleri JC, Maher S et al.(2018). Burden of ulcerative colitis on functioning and well-being: A systematic literature review of the SF-36® Health Survey. Journal of Crohn's and Colitis vol. 12, (5) 600-609.

Pockley AG, Lindsay JO, Foulds GA, Rutella S, Gribben JG, Alexander T, Snowden JA(2018). Immune Reconstitution After Autologous Hematopoietic Stem Cell Transplantation in Crohn's Disease: Current Status and Future Directions. A Review on Behalf of the EBMT Autoimmune Diseases Working Party and the Autologous Stem Cell Transplantation In Refractory CD-Low Intensity Therapy Evaluation Study Investigators. Front Immunol vol. 9, 646-646.

Snowden JA, Panés J, Alexander T, Allez M, Ardizzone S, Dierickx D, Finke J, Hasselblatt P et al.(2018). Autologous haematopoietic stem cell transplantation (AHSCT) in severe Crohn's disease: A review on behalf of ECCO and EBMT. Journal of Crohn's and Colitis vol. 12, (4) 1-13.

Irving PM, Iqbal T, Nwokolo C, Subramanian S, Bloom S, Prasad N, Hart A, Murray C et al.(2018). A Randomized, Double-blind, Placebo-controlled, Parallel-group, Pilot Study of Cannabidiol-rich Botanical Extract in the Symptomatic Treatment of Ulcerative Colitis. Inflammatory Bowel Diseases vol. 24, (4) 714-724.

Rossi M, Aggio R, Staudacher HM, Lomer MC, Lindsay JO, Irving P, Probert C, Whelan K(2018). Volatile Organic Compounds in Feces Associate With Response to Dietary Intervention in Patients With Irritable Bowel Syndrome. Clinical Gastroenterology and Hepatology vol. 16, (3) 385-391.e1.

Snowden J, Panes J, Alexander T, Allez M, Ardizzone S, Dierickx D, Finke J, Hasselblatt P et al. (2018). ECCO-EBMT joint paper: autologous haematopoietic stem cell transplantation (AHSCT) in severe Crohn's disease: Summary of the ECCO-EBMT joint review. JOURNAL OF CROHNS & COLITIS. vol. 12, S70-S71.

Sands BE, Moss AC, Armuzzi A, Marshall JK, Lindsay JO, Sandborn WJ, Danese S, Tsilkos K et al. (2018). Efficacy and safety of dose escalation to tofacitinib 10 mg BID for patients with ulcerative colitis following loss of response on tofacitinib 5 mg BID maintenance therapy: results from OCTAVE open. JOURNAL OF CROHNS & COLITIS. vol. 12, S49-S49.

Mehta SJ, Lewis A, Nijhuis A, Jeffery R, Feakins R, Silver A, Lindsay JO (2018). Epithelial to mesenchymal transition is a hallmark of fibrostenosing Crohn's disease and is associated with down regulation of the miR-200 family. JOURNAL OF CROHNS & COLITIS. vol. 12, S91-S92.

Bossuyt P, Atreya R, Taxonera C, Hebuterne X, Isaacs K, Higgins PD, Lindsay J, Heap G et al. (2018). Long-term safety of adalimumab in patients with moderate-to-severe ulcerative colitis: Interim results of a non-interventional registry, LEGACY. JOURNAL OF CROHNS & COLITIS. vol. 12, S32-S32.

Cox S, Stagg A, Fromentin S, Ehrlich D, McCarthy N, Galleron N, Levenez F, Lomer M et al. (2018). Low FODMAP diet improves functional-like gastrointestinal symptoms but reduces bifidobacteria and faecalibacterium prausnitzii in Quiescent inflammatory bowel disease: a randomised controlled trial and metagenomic analysis. JOURNAL OF CROHNS & COLITIS. vol. 12, S87-S87.

Gordon H, Gadhok R, Ibarra A, Lindsay JO (2018). UK Asians are prescribed vedolizumab earlier in disease history than Caucasians, but respond equally well to therapy. JOURNAL OF CROHNS & COLITIS. vol. 12, S459-S459.

Panés J, Vermeire S, Lindsay JO, Sands BE, Su C, Friedman G, Zhang H, Yarlas A et al.(2018). Tofacitinib in patients with ulcerative colitis: Health-related quality of life in phase 3 randomised controlled induction and maintenance studies. Journal of Crohn's and Colitis vol. 12, (2) 145-156.

Brooks AJ, Smith PJ, Lindsay JO(2018). Monitoring adolescents and young people with inflammatory bowel disease during transition to adult healthcare. Frontline Gastroenterology vol. 9, (1) 37-44.

Rigoni A, Poulsom R, Jeffery R, Mehta S, Lewis A, Yau C, Giannoulatou E, Feakins R et al.(2017). Separation of Dual Oxidase 2 and Lactoperoxidase Expression in Intestinal Crypts and Species Differences May Limit Hydrogen Peroxide Scavenging During Mucosal Healing in Mice and Humans. Inflamm Bowel Dis vol. 24, (1) 136-148.

Ball JA, Clear AJ, Calaminici M, Stagg A, Lindsay J, Gribben JG, Davies J (2017). Human Gastro-Intestinal Graft-VersusHost Disease Is Mediated By Retinoic Acid-Responsive CD8(+)Effector T-Cells Under IL-23 Polarising Conditions. BLOOD. vol. 130,

Staudacher HM, Lomer MCE, Farquharson FM, Louis P, Fava F, Franciosi E, Scholz M, Tuohy KM et al.(2017). A Diet Low in FODMAPs Reduces Symptoms in Patients With Irritable Bowel Syndrome and A Probiotic Restores Bifidobacterium Species: A Randomized Controlled Trial. Gastroenterology vol. 153, (4) 936-947.

Lindsay JO(2017). Autologous stem cell transplantation for refractory Crohn's disease: Is it time to take a long-term view?. Journal of Crohn's and Colitis vol. 11, (10) 1157-1158.

Lindsay JO, Armuzzi A, Gisbert JP, Bokemeyer B, Peyrin-Biroulet L, Nguyen GC, Smyth M, Patel H(2017). Indicators of suboptimal tumor necrosis factor antagonist therapy in inflammatory bowel disease. Digestive and Liver Disease vol. 49, (10) 1086-1091.

van Rheenen PF, Aloi M, Biron IA, Carlsen K, Cooney R, Cucchiara S, Cullen G, Escher JC et al.(2017). European Crohn's and Colitis Organisation topical review on transitional care in inflammatory bowel disease. Journal of Crohn's and Colitis vol. 11, (9) 1032-1038.

Gadhok R, Gordon H, Sebepos-Rogers G, Baillie S, Akbar S, Ahmad OF, Cooper B, Lindsay JO (2017). ANTI-TNFS MORE FREQUENTLY STOPPED DUE TO LOSS OF RESPONSE IN BRITISH ASIANS WITH CROHN'S DISEASE: A SINGLE CENTRE RETROSPECTIVE ANALYSIS. GUT. vol. 66, A255-A255.

Panés J, Rubin D, Vermeire S, Lindsay J, Sands B, Su C, Friedman G, Zhang H et al. (2017). AODWE-004 Maintenance of quality of life improvement in a phase 3 study of tofacitinib for patients with moderately to severely active ulcerative colitis. Gut. vol. 66,

Lindsay JO, Allez M, Clark M, Labopin M, Ricart E, Rogler G, Rovira M, Satsangi J et al.(2017). Autologous stem-cell transplantation in treatment-refractory Crohn's disease: an analysis of pooled data from the ASTIC trial. The Lancet Gastroenterology & Hepatology vol. 2, (6) 399-406.

Brooks AJ, Smith PJ, Cohen R, Collins P, Douds A, Forbes V, Gaya DR, Johnston BT et al.(2017). UK guideline on transition of adolescent and young persons with chronic digestive diseases from paediatric to adult care. Gut vol. 66, (6) 988-1000.

Yarlas A, Sands BE, Rubin DT, Lindsay J, Panes J, Vermeire S, Chen LA, Bayliss M et al. (2017). A SYSTEMATIC REVIEW OF THE INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE FOR MEASURING HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH ULCERATIVE COLITIS. VALUE IN HEALTH. vol. 20, A185-A185.

Gordon H, Gadhok R, Sebepos-Rogers G, Baillie S, Akbar S, Ahmad OF, Cooper BE, Lindsay JO (2017). Sa1833 Anti-TNFS More Frequently Stopped Due to Loss of Response in British Asians with Crohn's Disease: A Single Centre Retrospective Analysis. Gastroenterology. vol. 152,

Gordon H, Hoti I, Lindsay JO, Stagg AJ (2017). Tu1908 Circulating Non-Classical Monocytes are Reduced in Patients with Active IBD but Increase after Vedolizumab: A Role for α4β7 in Myeloid Cell Recruitment to the Inflamed Intestine. Gastroenterology. vol. 152, s1003-s1004.

MCCARTHY NE, Tyler CJ, Lindsay JO, Stagg AJ, Moser B, Eberl M(2017). Antigen-presenting human γδ T-cells promote intestinal CD4+ T-cell expression of IL-22 and mucosal release of calprotectin. Journal of Immunology

Lewis A, Felice C, Kumagai T, Lai C, Singh K, Jeffery RR, Feakins R, Giannoulatou E et al.(2017). The miR-200 family is increased in dysplastic lesions in ulcerative colitis patients. PLoS One vol. 12, (3) e0173664-e0173664.

Nijhuis A, Curciarello R, Mehta S, Feakins R, Bishop CL, Lindsay JO, Silver A(2017). MCL-1 is modulated in Crohn's disease fibrosis by miR-29b via IL-6 and IL-8. Cell Tissue Res

Hedin CR, van der Gast CJ, Stagg AJ, Lindsay JO, Whelan K(2017). The gut microbiota of siblings offers insights into microbial pathogenesis of inflammatory bowel disease. Gut Microbes vol. 8, (4) 359-365.

Gadhok R, Gordon H, Sebepos-Rogers G, Baillie S, Akbar S, Ahmad OF, Cooper B, Lindsay JO (2017). Anti-TNFs more frequently stopped due to loss of response in British Asians with Crohn's disease: a single centre retrospective analysis. JOURNAL OF CROHNS & COLITIS. vol. 11, S393-S393.

Gordon H, Hoti I, Lindsay JO, Stagg A (2017). Circulating non-classical monocytes are reduced in patients with active IBD but increase after vedolizumab: a role for alpha 4 beta 7 in myeloid cell recruitment to the inflamed intestine. JOURNAL OF CROHNS & COLITIS. vol. 11, S104-S105.

Lewis A, Felice C, Nihjuis A, Iqbal S, Mehta S, Feakins R, Armuzzi A, Silver A et al. (2017). Hypoacetylation of histone-3 is a hallmark of intestinal fibrosis in Crohn's disease. JOURNAL OF CROHNS & COLITIS. vol. 11, S17-S17.

Perez Gisbert J, Patel H, Nguyen G, Bokemeyer B, Armuzzi A, Lindsay J, Khalid J, Peyrin-Biroule L (2017). Impact of Dose Escalation with Anti-TNFs on Healthcare Resource Utilization Among Patients with Crohn's Disease: A Multi-Country Chart Review. INFLAMMATORY BOWEL DISEASES. vol. 23, S25-S25.

Tranter M, Barakat F, Dogra H, Lindsay J, Croft N, Bulmer D (2017). MMP-12, a novel mediator of nociception in Crohn's disease. JOURNAL OF CROHNS & COLITIS. Conference: European Crohn's and Colitis (ECCO) Congress 2017 vol. 11, S120-S120.

McCarthy N, Gordon H, Rahman S, Harrow P, Stagg A, Lindsay J (2017). Mucosal inflammation promotes activation of circulating Vd2+T-cells in Crohn's disease. JOURNAL OF CROHNS & COLITIS. vol. 11, S107-S107.

Le Bourhis L, Corraliza A, Auzolle C, Ricart E, Hawkey C, Lindsay JO, Clark M, Rogler G et al.(2017). OP004 Resetting of the mucosal T cell repertoire after hematopoietic stem cell transplantation in refractory Crohn's disease. J Crohns Colitis vol. 11, (suppl_1) S2-S3.

McCarthy N, Gordon H, Rahman S, Harrow P, Stagg A, Lindsay J (2017). P059 Mucosal inflammation promotes activation of circulating Vδ2+ T-cells in Crohn's disease. J Crohns Colitis. vol. 11,

Tranter M, Barakat F, Dogra H, Lindsay J, Croft N, Bulmer D (2017). P086 MMP-12, a novel mediator of nociception in Crohn's disease. J Crohns Colitis. vol. 11, S120-S120.

Panés J, Rubin DT, Vermeire S, Lindsay JO, Sands BE, Su C, Friedman G, Zhang H et al.(2017). P467 Maintenance of quality of life improvement in a phase 3 study of tofacitinib for patients with moderately to severely active ulcerative colitis. J Crohns Colitis vol. 11, (suppl_1) S315-S317.

Rubin DT, Panés J, Lindsay JO, Vermeire S, Yarlas A, Bayliss M, Cappelleri JC, Maher S et al.(2017). P558 The SF-36® Health Survey distinguishes disease burden on functioning and well-being between patients with active vs inactive ulcerative colitis. J Crohns Colitis vol. 11, (suppl_1) S364-S365.

Le Bourhis L, Corraliza A, Auzolle C, Ricart E, Hawkey C, Lindsay JO, Clark M, Rogler G et al. (2017). Resetting of the mucosal T cell repertoire after hematopoietic stem cell transplantation in refractory Crohn's disease. JOURNAL OF CROHNS & COLITIS. vol. 11, S2-S3.

McCartney S, Lindsay J, Russell R, Gaya D, Shaw I, Murray C, Finney-Hayward T, Sebastian S (2017). Structured transition enhances clinical outcome without an increase in healthcare cost in adolescent patients with IBD: the UK TRANSIT study. JOURNAL OF CROHNS & COLITIS. vol. 11, S356-S357.

Hoti I, McCarthy NE, Giles EM, Ayada I, Gordon H, Stagg AJ, Lindsay JO (2017). TNF alpha production by classical monocytes is poorly controlled by IL-10 in patients with IBD. JOURNAL OF CROHNS & COLITIS. Conference: 12th Congress of ECCO - European Crohn's and Colitis Organisation (Barcelona, Spain) from: 18/02/2017 to: 15/02/2017, vol. 11, S112-S112.

Rubin DT, Panes J, Lindsay JO, Vermeire S, Yarlas A, Bayliss M, Cappelleri JC, Maher S et al. (2017). The SF-36r\(R) Health Survey distinguishes disease burden on functioning and well-being between patients with active vs inactive ulcerative colitis. JOURNAL OF CROHNS & COLITIS. vol. 11, S364-S365.

McCartney S, Lindsay J, Russell R, Gaya D, Shaw I, Murray C, Finney-Hayward T, Sebastian S (2017). The impact of transition to adult gastroenterology services on health-related quality of life in young adult patients with IBD: the UK TRANSIT study. JOURNAL OF CROHNS & COLITIS. vol. 11, S261-S262.

Gomollón F, Dignass A, Annese V, Tilg H, Van Assche G, Lindsay JO, Peyrin-Biroulet L, Cullen GJ et al.(2017). 3rd European evidence-based consensus on the diagnosis and management of Crohn's disease 2016: Part 1: Diagnosis and medical management. Journal of Crohn's and Colitis vol. 11, (1) 3-25.

Cox S, Prince A, Myers C, Irving PM, Lindsay JO, Lomer MC, Whelan K (2017). Fermentable carbohydrates (FODMAPs) as triggers of functional gastrointestinal symptoms in patients with inflammatory bowel disease: a randomised, double-blind, placebo-controlled, cross-over, re-challenge trial. Proceedings of The Nutrition Society. vol. 76,

Cox SR, Prince AC, Myers CE, Irving PM, Lindsay JO, Lomer MC, Whelan K(2017). Fermentable carbohydrates [FODMAPs] exacerbate functional gastrointestinal symptoms in patients with inflammatory bowel disease: A randomised, double-blind, placebo-controlled, cross-over, re-challenge trial. Journal of Crohn's and Colitis vol. 11, (12) 1420-1429.

Giles EM, Sanders TJ, McCarthy NE, Lung J, Pathak M, Macdonald TT, Lindsay JO, Stagg AJ(2017). Regulation of human intestinal T-cell responses by type 1 interferon-STAT1 signaling is disrupted in inflammatory bowel disease. Mucosal Immunology vol. 10, (1) 184-193.

Khalid JM, Peyrin-Biroulet L, Armuzzi A, Gisbert JP, Nguyen G, Bokemeyer B, Lindsay J, Smyth M et al. (2016). Predictors of Non-response or Loss of Response to Tumour Necrosis Factor Antagonist Therapies in Inflammatory Bowel Disease. The American Journal of Gastroenterology. vol. 111,

Peyrin-Biroulet L, Germain A, Patel AS, Lindsay JO(2016). Systematic review: outcomes and post-operative complications following colectomy for ulcerative colitis. Alimentary Pharmacology and Therapeutics vol. 44, (8) 807-816.

Walton S-J, Lewis A, Jeffery R, Thompson H, Feakins R, Giannoulatou E, Yau C, Lindsay JO et al.(2016). Familial adenomatous patients with desmoid tumours show increased expression of miR-34a in serum and high levels in tumours. Oncoscience vol. 3, (5-6) 173-185.

Hawkey CJ, Lindsay J, Gribben J(2016). In reply. JAMA - Journal of the American Medical Association vol. 315, (23) 2620-2621.

Lindsay J, Gisbert J, Mody R, Peyrin-Biroulet L, Armuzzi A, Bokemeyer B, Nguyen G, Siebenaler J et al. (2016). PTH-070 A Multinational Study to Determine Indicators of Suboptimal Therapy Among Ulcerative Colitis Patients Treated with Tumour Necrosis Factor Antagonists. Gut. vol. 65,

Armuzzi A, Lindsay J, Mody R, Bokemeyer B, Gisbert J, Peyrin-Biroulet L, Nguyen G, Siebenaler J et al. (2016). PTH-071 Indicators of Suboptimal Therapy Among Crohn’s Disease Patients Treated with Tumour Necrosis Factor Antagonists: Results from A Multi-National Study. Gut. vol. 65,

Harrow P, Skinner C, Hoque T, Ibarra A, Lindsay J (2016). PTU-068 Dose Optimisation Using Drug and Antibody Levels Can Benefit 50% Patients Prescribed Anti TNF Therapy Compared to Empiric Dose Adjustment. Gut. vol. 65,

Hedin C, Van Der Gast CJ, Rogers GB, Cuthbertson L, McCartney S, Stagg AJ, Lindsay JO, Whelan K(2016). Siblings of patients with Crohn's disease exhibit a biologically relevant dysbiosis in mucosal microbial metacommunities. Gut vol. 65, (6) 944-953.

Kennedy NA, Warner B, Johnston EL, Flanders L, Hendy P, Ding NS, Harris R, Fadra AS et al.(2016). Relapse after withdrawal from anti-TNF therapy for inflammatory bowel disease: An observational study, plus systematic review and meta-analysis. Alimentary Pharmacology and Therapeutics vol. 43, (8) 910-923.

Harrow P, Skinner C, Hoque T, Ibarra A, Lindsay J (2016). Dose optimisation using drug and antibody levels can benefit 50% patients prescribed anti-TNF therapy compared with empiric dose adjustment. JOURNAL OF CROHNS & COLITIS. vol. 10, S71-S72.

Cox S, Prince A, Myers C, Irving PM, Lindsay JO, Lomer MC, Whelan K (2016). Fermentable carbohydrates (FODMAPs) as triggers of functional gastrointestinal symptoms in patients with quiescent inflammatory bowel disease: a double-blind, placebo-controlled, randomised, cross-over re-challenge trial. JOURNAL OF CROHNS & COLITIS. vol. 10, S342-S342.

Tyler C, McCarthy N, Moser B, Stagg A, Eberl M, Lindsay J(2016). Human intestinal V delta 2+T-cells acquire antigen-presenting potency upon exposure to microbial phosphoantigen: modulation by mucosal inflammation and vedolizumab therapy. JOURNAL OF CROHNS & COLITIS vol. 10, S29-S29.

Lindsay J, Allez M, Clark M, Labopin M, Ricart E, Rogler G, Rovira M, Satsangi J et al. (2016). Prediction of clinical and endoscopic remission after autologous stem cell transplantation in treatment refractory Crohn's disease: pooled results from the ASTIC trial. JOURNAL OF CROHNS & COLITIS. vol. 10, S37-S38.

Arnott I, Mowat C, Ennis H, Keerie C, Lewis S, Kennedy N, Cahill A, Morris A et al. (2016). The TOPPIC Trial: a randomised, double-blind parallel-group trial of mercaptopurine versus placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. JOURNAL OF CROHNS & COLITIS. vol. 10, S21-S22.

Hughes LD, King L, Morgan M, Ayis S, Direkze N, Lomer MC, Lindsay JO, Whelan K(2016). Food-related quality of life in inflammatory bowel disease: Development and validation of a questionnaire. Journal of Crohn's and Colitis vol. 10, (2) 1-8.

Mowat C, Arnott I, Cahill A, Smith M, Ahmad T, Subramanian S, Travis S, Morris J et al.(2016). Mercaptopurine versus placebo to prevent recurrence of Crohn's disease after surgical resection (TOPPIC): a multicentre, double-blind, randomised controlled trial. The Lancet Gastroenterology and Hepatology vol. 1, (4) 273-282.

Torres J, Caprioli F, Katsanos KH, Lobatón T, Micic D, Zerôncio M, Assche GV, Lee JC et al.(2016). Predicting outcomes to optimize disease management in inflammatory bowel diseases. Journal of Crohn's and Colitis vol. 10, (12) 1385-1394.

Hawkey CJ, Allez M, Clark MM, Labopin M, Lindsay JO, Ricart E, Rogler G, Rovira M et al.(2015). Autologous hematopoetic stem cell transplantation for refractory Crohn disease a randomized clinical trial. JAMA - Journal of the American Medical Association vol. 314, (23) 2524-2534.

Anderson JL, Hedin CR, Benjamin JL, Koutsoumpas A, Ng SC, Hart AL, Forbes A, Stagg AJ et al.(2015). Dietary intake of inulin-type fructans in active and inactive Crohn's disease and healthy controls: A case-control study. Journal of Crohn's and Colitis vol. 9, (11) 1024-1031.

McCarthy NE, Hedin CR, Sanders TJ, Amon P, Hoti I, Ayada I, Baji V, Giles EM et al.(2015). Azathioprine therapy selectively ablates human Vδ2+ T cells in Crohn’s disease. Journal of Clinical Investigation vol. 125, (8) 3215-3225.

Mehta S, Nijhuis A, Kumagai T, Lindsay J, Silver A(2015). Defects in the adherens junction complex (E-cadherin/ β-catenin) in inflammatory bowel disease. Cell Tissue Res vol. 360, (3) 749-760.

Kennedy N, Lindsay J, Gordon J, Hart A, McCartney S, Irving P, Satsangi J, Lees C (2015). OC-009 Withdrawal of anti-tnf following sustained remission for inflammatory bowel disease: a systematic review and meta-analysis. Gut. vol. 64,

Parisinos C, Ooi J, Lindsay J, Parkes G (2015). OC-034 Probiotics for the prevention of antibiotic associated diarrhoea in the older inpatient population; a systematic review and meta-analysis. Gut. vol. 64,

Staudacher H, Lomer M, Lindsay J, Irving P, Whelan K (2015). OC-103 The impact of low fodmap dietary advice and probiotics on symptoms in irritable bowel syndrome: a randomised, placebo-controlled, 2 × 2 factorial trial. Gut. vol. 64,

Irving P, Iqbal T, Nwokolo C, Subramanian S, Bloom S, Prasad N, Hart A, Murray C et al. (2015). PTH-056 Trial to assess cannabidiol in the symptomatic treatment of ulcerative colitis. Gut. vol. 64,

Tandiari T, Ibarra A, Younge L, Allepuz AP, Thompson A, Meade U, Arkir Z, Giles E et al. (2015). PTH-083 Selective monitoring of antitnf drug levels and antibodies will reduce short-term prescribing costs and provide early personalised tailoring of antitnf therapy in routine ibd practice. Gut. vol. 64,

Hawkey C, Allez M, Clark M, Labopin M, Lindsay J, Ricart E, Rogler G, Satsangi J et al. (2015). PTU-082 Responders to haemopoietic stem cell transplantation for crohn’s disease. Gut. vol. 64,

Sharratt C, Hawkey C, Allez M, Clark M, Labopin M, Lindsay J, Ricart E, Rogler G et al. (2015). PTU-083 Substantial histological improvement following haemopoetic stem cell transplantation. Gut. vol. 64,

Biancheri P, Di Sabatino A, Curciarello R, Ammoscato F, Corazza GR, Lindsay JO, MacDonald TT (2015). Interleukin-17A Homodimer Reduces Pro-Inflammatory Cytokine Production by Inflammatory Bowel Disease Mucosa Cultured Ex Vivo. GASTROENTEROLOGY. vol. 148, S695-S695.

Kennedy NA, Warner B, Johnston E, Flanders L, Hendy P, Ding N, Harris R, Fadra AS et al.(2015). Anti-TNF withdrawal in IBD: Relapse and recapture rates and predictive factors from 160 patients in a pan-UK study. JOURNAL OF CROHNS & COLITIS vol. 9, S41-S42.

Younge L, Lindsay J, Langmead L, Czuber-Dochan W(2015). Assessing the satisfaction levels of older patients with different types of follow-up care for inflammatory bowel disease. JOURNAL OF CROHNS & COLITIS vol. 9, S444-S445.

Irving P, Iqbal T, Nwokolo C, Subramanian S, Bloom S, Prasad N, Hart A, Murray C et al.(2015). Cannabidiol for symptomatic treatment of ulcerative colitis: Results from a randomised, double-blind, placebo-controlled, parallel group, multi-centred pilot study. JOURNAL OF CROHNS & COLITIS vol. 9, S287-S287.

Peyrin-Biroulet L, Patel AS, Lindsay JO(2015). Colectomy is not a cure for ulcerative colitis: A systematic review. JOURNAL OF CROHNS & COLITIS vol. 9, S280-S281.

Hawkey C, Allez M, Clark M, Labopin M, Lindsay J, Ricart E, Rogler G, Satsangi J et al.(2015). Prolonged Deep Remission of Ileocolonic Crohn's Disease following Autologous Haemopoetic Stem Cell Transplantation, presented on behalf of all the ASTIC Trialists. JOURNAL OF CROHNS & COLITIS vol. 9, S11-S12.

Lindsay JO, Peyrin-Biroulet L, Patel AS, Bergman A(2015). Systematic review: The financial burden of surgical complications in patients with ulcerative colitis. JOURNAL OF CROHNS & COLITIS vol. 9, S232-S233.

Parisinos CA, Harrow P, Langmead L, van Heel DA, Lindsay JO(2015). eHealth optimises documentation and enables live access to IBD Multi Disciplinary Team outcomes. JOURNAL OF CROHNS & COLITIS vol. 9, S366-S367.

Andreyev HJN, Muls AC, Norton C, Ralph C, Watson L, Shaw C, Lindsay JO(2015). Guidance: The practical management of the gastrointestinal symptoms of pelvic radiation disease. Frontline Gastroenterol vol. 6, (1) 53-72.

Alexakis C, Nash A, Lloyd M, Brooks F, Lindsay JO, Poullis A(2015). Inflammatory bowel disease in young patients: Challenges faced by black and minority ethnic communities in the UK. Health and Social Care in the Community vol. 23, (6) 665-672.

Lewis A, Nijhuis A, Mehta S, Kumagai T, Feakins R, Lindsay JO, Silver A(2015). Intestinal fibrosis in crohn's disease: Role of microRNAs as fibrogenic modulators, serum biomarkers, and therapeutic targets. Inflammatory Bowel Diseases vol. 21, (5) 1141-1150.

Lewis A, Mehta S, Hanna LN, Rogalski LA, Jeffery R, Nijhuis A, Kumagai T, Biancheri P et al.(2015). Low serum levels of microRNA-19 are associated with a stricturing Crohn's disease phenotype. Inflammatory Bowel Diseases vol. 21, (8) 1926-1934.

Felice C, Lewis A, Armuzzi A, Lindsay JO, Silver A(2015). Review article: selective histone deacetylase isoforms as potential therapeutic targets in inflammatory bowel diseases. Aliment Pharmacol Ther vol. 41, (1) 26-38.

Lindsay JO, Bergman A, Patel AS, Alesso SM, Peyrin-Biroulet L(2015). Systematic review: The financial burden of surgical complications in patients with ulcerative colitis. Alimentary Pharmacology and Therapeutics

McCarthy NE, Hedin CR, Sanders TJ, Amon P, Baji V, Giles EM, Wildemann M, Bashir Z et al. (2014). Colonic V delta 2+T-cells display elevated TNF production and reversible ablation by azathioprine therapy in Crohn's disease. IMMUNOLOGY. vol. 143, 165-165.

Giles E, Sanders TJ, McCarthy NE, Sanderson I, Lindsay J, MacDonald TT, Stagg AJ (2014). Constitutive Type I Interferon, via STAT1 activation, selectively promotes regulatory T cell function in the healthy human intestine, but not in IBD. IMMUNOLOGY. vol. 143, 17-17.

Heap GA, Weedon MN, Bewshea CM, Singh A, Chen M, Satchwell JB, Vivian JP, So K et al.(2014). HLA-DQA1-HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants. Nat Genet vol. 46, (10) 1131-1134.

Heap GA, Weedon MN, Bewshea CM, Singh A, Chen M, Satchwell JB, Vivian JP, So K et al.(2014). HLA-DQA1-HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants. Nature Genetics vol. 46, (10) 1131-1134.

Lindsay J(2014). Psychosocial aspects of IBD in paediatric and adolescent patients: The impact of transition. Psychological Aspects of Inflammatory Bowel Disease: A Biopsychosocial Approach,

Nijhuis A, Biancheri P, Lewis A, Bishop CL, Giuffrida P, Chan C, Feakins R, Poulsom R et al.(2014). In Crohn's disease fibrosis-reduced expression of the miR-29 family enhances collagen expression in intestinal fibroblasts. Clin Sci (Lond) vol. 127, (5) 341-350.

Parkes GC, Whelan K, Lindsay JO(2014). Smoking in inflammatory bowel disease: Impact on disease course and insights into the aetiology of its effect. Journal of Crohn's and Colitis vol. 8, (8) 717-725.

Heap G, Singh A, Bewshea C, Weedon M, Cole A, Creed T, Greig E, Irving P et al.(2014). OC-004 Thiopurine Induced Pancreatitis In Inflammatory Bowel Disease: Clinical Features And Genetic Determinants. Gut vol. 63 Suppl 1, A2-A3.

Hedin C, van der Gast C, Rogers G, McCartney S, Stagg A, Lindsay J, Whelan K(2014). OC-051 Siblings Of Crohn's Disease Patients Exhibit A Biologically Relevant Dysbiosis In The Mucosal Microbial Community: A 16s Rrna Gene Pyrosequencing Study. Gut vol. 63 Suppl 1,

Hughes L, Lindsay J, Lomer M, Ayis S, King L, Morgan M, Whelan K(2014). PTU-102 Development Of A Food Related Quality Of Life Questionnaire For People With Ibd. Gut vol. 63 Suppl 1,

Russo E, Hackett R, Campbell S, Lindsay J, Irving P, Orchard T(2014). PWE-071 Efficacy Of Infliximab As Second-line Biologic In Crohn's Disease. Gut vol. 63 Suppl 1, A154-A155.

Biancheri P, Di Sabatino A, Curciarello R, Corazza G, Lindsay J, MacDonald T(2014). PWE-087 Interleukin-17a Homodimer Reduces Pro-inflammatory Cytokine Production By Inflammatory Bowel Disease Mucosa Cultured Ex Vivo. Gut vol. 63 Suppl 1,

Heap GA, Singh A, Bewshea CM, Weedon M, Dubois P, Andrews JM, Annese V, Bampton PA et al.(2014). 6 Thiopurine Induced Pancreatitis in Inflammatory Bowel Disease: Clinical Features and Genetic Determinants. Gastroenterology vol. 146, (5) s-2.

Giles E, Pathak M, Sanders TJ, McCarthy NE, Sanderson IR, Thomas M, Lindsay JO, Stagg AJ (2014). Constitutive Type I Interferon, via STAT1 Activation, Selectively Promotes Regulatory T Cell Function in the Healthy Human Intestine, but Not in Inflammatory Bowel Disease. GASTROENTEROLOGY. vol. 146, S293-S294.

Sanders TJ, McCarthy NE, Giles EM, Davidson KLM, Haltalli MLR, Hazell S, Lindsay JO, Stagg AJ(2014). Increased production of retinoic acid by intestinal macrophages contributes to their inflammatory phenotype in patients with Crohn's disease. Gastroenterology vol. 146, (5)

Heap GA, Singh A, Bewshea CM, Weedon M, Dubois P, Andrews JM, Annese V, Bampton PA et al. (2014). Thiopurine Induced Pancreatitis in Inflammatory Bowel Disease: Clinical Features and Genetic Determinants. GASTROENTEROLOGY. vol. 146, S2-S2.

MacFie TS, Poulsom R, Parker A, Warnes G, Boitsova T, Nijhuis A, Suraweera N, Poehlmann A et al.(2014). DUOX2 and DUOXA2 form the predominant enzyme system capable of producing the reactive oxygen species H2O2 in active ulcerative colitis and are modulated by 5-aminosalicylic acid. Inflamm Bowel Dis vol. 20, (3) 514-524.

Hedin C, van der Gast C, Rogers G, McCartney S, Stagg AJ, Lindsay JO, Whelan K(2014). OP020 16S rRNA gene pyrosequencing indicate that siblings of Crohn's disease patients exhibit a biologically relevant dysbiosis in the mucosal microbiota communities. Journal of Crohn's and Colitis vol. 8, s11-s12.

Biancheri P, Di Sabatino A, Curciarello R, Giuffrida P, Ammoscato F, Corazza GR, Lindsay JO, MacDonald TT(2014). P053 Interleukin-17A homodimer reduces pro-inflammatory cytokine production by inflammatory bowel disease mucosa cultured ex vivo. Journal of Crohn's and Colitis vol. 8,

Hedin CR, McCarthy NE, Louis P, Farquharson FM, McCartney S, Taylor K, Prescott NJ, Murrells T et al.(2014). Altered intestinal microbiota and blood T cell phenotype are shared by patients with Crohn's disease and their unaffected siblings. Gut

Dignass A, Eliakim R, Magro F, Maaser C, Chowers Y, Geboes K, Mantzaris G, Reinisch W et al.(2014). Second European evidence-based Consensus on the diagnosis and management of ulcerative colitis Part 1: Definitions and diagnosis. Revista de Gastroenterologia de Mexico vol. 79, (4) 263-289.

Parkes GC, Whelan K, Lindsay JO(2014). Smoking in inflammatory bowel disease: Impact on disease course and insights into the aetiology of its effect. Journal of Crohn's and Colitis

Kennedy NA, Kalla R, Warner B, Gambles CJ, Musy R, Reynolds S, Dattani R, Nayee H et al.(2014). Thiopurine withdrawal during sustained clinical remission in inflammatory bowel disease: Relapse and recapture rates, with predictive factors in 237 patients. Alimentary Pharmacology and Therapeutics vol. 40, (11-12) 1313-1323.

Andreyev HJN, Benton BE, Lalji A, Norton C, Mohammed K, Gage H, Pennert K, Lindsay JO(2013). Algorithm-based management of patients with gastrointestinal symptoms in patients after pelvic radiation treatment (ORBIT): a randomised controlled trial. Lancet vol. 382, (9910) 2084-2092.

Giles E, Pathak M, Sanders TJ, McCarthy NE, Sanderson IR, MacDonald TT, Lindsay JO, Stagg AJ (2013). Constitutive Type I Interferon, via STAT1 activation, promotes regulatory T cell function in the healthy human intestine, but not in inflammatory bowel disease. IMMUNOLOGY. vol. 140, 168-168.

Sanders TJ, McCarthy NE, Giles EM, Davidson KLM, Haltalli MLR, Hazell S, Lindsay JO, Stagg AJ (2013). Retinoic acid generation by human intestinal CD14(+) macrophages is enhanced in Crohn's disease and maintains an inflammatory phenotype. IMMUNOLOGY. vol. 140, 32-32.

Goodhand JR, Kamperidis N, Sirwan B, Macken L, Tshuma N, Koodun Y, Chowdhury FA, Croft NM et al.(2013). Factors associated with thiopurine non-adherence in patients with inflammatory bowel disease. Aliment Pharmacol Ther vol. 38, (9) 1097-1108.

Allison M, Lindsay J, Gould D, Kelly D(2013). Surgery in young adults with inflammatory bowel disease: a narrative account. Int J Nurs Stud vol. 50, (11) 1566-1575.

McCarthy NE, Bashir Z, Vossenkämper A, Hedin CR, Giles EM, Bhattacharjee S, Brown SG, Sanders TJ et al.(2013). Proinflammatory Vδ2+ T cells populate the human intestinal mucosa and enhance IFN-γ production by colonic αβ T cells. J Immunol vol. 191, (5) 2752-2763.

Lindsay JO, Chipperfield R, Giles A, Wheeler C, Orchard T, INDIGO study investigators(2013). A UK retrospective observational study of clinical outcomes and healthcare resource utilisation of infliximab treatment in Crohn's disease. Aliment Pharmacol Ther vol. 38, (1) 52-61.

Mehta SJ, Silver AR, Lindsay JO(2013). Review article: strategies for the management of chronic unremitting ulcerative colitis. Aliment Pharmacol Ther vol. 38, (2) 77-97.

Andreyev HJ, Benton B, Lalji A, Pennert K, Lindsay JO, Gage H, Norton C (2013). ALGORITHMIC MANAGEMENT OF RADIATION-INDUCED GI SYMPTOMS IS HIGHLY EFFECTIVE: THE ORBIT RANDOMISED CONTROLLED TRIAL. GUT. vol. 62, A29-A30.

Landy J, Wahed M, Peake STC, Hussein M, Ng SC, Lindsay JO, Hart AL(2013). Oral tacrolimus as maintenance therapy for refractory ulcerative colitis-an analysis of outcomes in two London tertiary centres. Journal of Crohn's and Colitis vol. 7, (11)

Hawkey C, Allez M, Ardizzone S, Clark E, Clark M, Colombel JF, Danese S, Farge-Bancel D et al. (2013). Clinical and endoscopic improvement following haemopoietic stem cell transplantation on behalf of the Autoimmune Diseases Working Party of the EBMT. BONE MARROW TRANSPLANTATION. vol. 48, S44-S44.

Andreyev HJN, Benton BE, Lalji A, Norton C, Mohammed K, Gage H, Pennert K, Lindsay JO(2013). Algorithm-based management of patients with gastrointestinal symptoms in patients after pelvic radiation treatment (ORBIT): A randomised controlled trial. The Lancet vol. 382, (9910) 2084-2092.

Sanders TJ, McCarthy NE, Giles EM, Lindsay JO, Stagg AJ (2012). Retinoic acid production in the human intestine: antigen presenting cell retinaldehyde dehydrogenase activity is enhanced in inflammatory bowel disease. IMMUNOLOGY. vol. 137, 78-78.

Sebastian S, Jenkins H, McCartney S, Ahmad T, Arnott I, Croft N, Russell R, Lindsay JO(2012). The requirements and barriers to successful transition of adolescents with inflammatory bowel disease: Differing perceptions from a survey of adult and paediatric gastroenterologists. JOURNAL OF CROHNS & COLITIS vol. 6, (8) 830-844.

Macfie T, Parker A, Nijhuis A, Boitsova T, Suraweera N, Jeffery R, Poulsom R, Lindsay J et al.(2012). 5-ASA ENHANCES DUOX2 EXPRESSION IN ACTIVE ULCERATIVE COLITIS: A RISK FOR COLORECTAL CANCER?. GUT vol. 61, A401-A402.

Tshuma N, Aboulela S, Chowdhury F, Macken L, Kamperidis N, Goodhand J, Lindsay J(2012). BSG information group symposium & free papers: "Social media and apps: new opportunities, new risks" CONTENT ANALYSIS OF ILLNESS BLOGS POSTED ONLINE BY PATIENTS WITH IBD. GUT vol. 61, A68-A69.

McCarthy NE, Hedin CR, Vossenkaemper A, Bhattacharjee S, Brown SG, Sanders TJ, Giles EM, Whelan K et al. (2012). HUMAN ANTI-MICROBIAL V delta 2+T-CELLS ARE NOVEL INTESTINAL LYMPHOCYTES WITH FUNCTIONAL RELEVANCE IN CROHN'S DISEASE. GUT. vol. 61, A4-A4.

Sanders TJ, McCarthy NE, Giles E, Lindsay JO, Stagg AJ (2012). INTESTINAL INFLAMMATION REGULATES RETINOIC ACID DEPENDENT IMPRINTING OF GUT TROPISM BY DENDRITIC CELLS INDEPENDENTLY OF RALDH EXPRESSION. GUT. vol. 61, A402-A402.

Hedin CR, Taylor K, Louis P, Farquharson F, McCartney S, Prescott NJ, Stagg AJ, Lindsay JO et al.(2012). MICROBIAL, PHENOTYPIC AND GENETIC MARKERS OF RISK: ASPECTS OF CROHN'S DISEASE THAT ARE SHARED BY UNAFFECTED SIBLINGS. GUT vol. 61, A22-A23.

Nijhuis A, Biancheri P, Lai C, Ghosh A, Boitsova T, Chan C, MacDonald T, Lindsay J et al.(2012). MICRORNA EXPRESSION PROFILING IN STRICTURING CROHN'S DISEASE IDENTIFIES MIR-34A AS A FUNCTIONALLY RELEVANT INFLUENCE ON DISEASE PHENOTYPE. GUT vol. 61, A167-A168.

Andreyev HJ, Thomas K, Benton B, Lalji A, Lindsay JO, Gage H, Norton C(2012). OPTIMISING RADIATION BOWEL INJURY THERAPY, THE ORBIT STUDY, A RANDOMISED CONTROLLED TRIAL. GUT vol. 61, A36-A36.

Hedin CR, Louis P, Farquharson F, McCartney S, Stagg AJ, Lindsay JO, Whelan K(2012). PREBOTICS AS PRIMARY PREVENTION OF CROHN'S DISEASE: IMPACT ON LUMINAL MICROBIOLOGY AND ELEVATED FAECAL CALPROTECTIN IS GREATER IN HEALTHY SIBLINGS THAN IN PATIENTS. GUT vol. 61, A171-A171.

Sanders TJ, McCarthy NE, Giles EM, Lindsay JO, Stagg AJ (2012). THE ROLE OF RDH10 AND RALDH ENZYMES IN RETINOIC ACID-MEDIATED IMMUNE REGULATION BY ANTIGEN PRESENTING CELLS IN THE HUMAN INTESTINE. GUT. vol. 61, A402-A403.

Benjamin JL, Hedin CRH, Koutsoumpas A, Ng SC, McCarthy NE, Prescott NJ, Pessoa-Lopes P, Mathew CG et al.(2012). Smokers with active Crohn's disease have a clinically relevant dysbiosis of the gastrointestinal microbiota. INFLAMMATORY BOWEL DISEASES vol. 18, (6) 1092-1100.

Biancheri P, Nijhuis A, Lai C, Ghosh A, Feakins R, Chan C, Di Sabatino A, Corazza GR et al. (2012). Differential MicroRNA Expression Profiles in Crohn's Disease Strictured Versus Non-Strictured Intestine. GASTROENTEROLOGY. vol. 142, S877-S877.

Kamperidis N, Goodhand JR, Chowdhury FA, Koodun Y, Direzke NC, Naik S, Sanderson IR, Croft NM et al.(2012). Factors associated with nonadherence to thiopurines in adolescent and adult patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr vol. 54, (5) 685-689.

Goodhand JR, Kamperidis N, Joshi NM, Wahed M, Koodun Y, Cantor EJ, Croft NM, Langmead FL et al.(2012). The phenotype and course of inflammatory bowel disease in UK patients of Bangladeshi descent. Aliment Pharmacol Ther vol. 35, (8) 929-940.

Goodhand JR, Kamperidis N, Rao A, Laskaratos F, McDermott A, Wahed M, Naik S, Croft NM et al.(2012). Prevalence and management of anemia in children, adolescents, and adults with inflammatory bowel disease. Inflamm Bowel Dis vol. 18, (3) 513-519.

Hedin CR, Stagg AJ, Whelan K, Lindsay JO(2012). Family studies in Crohn's disease: new horizons in understanding disease pathogenesis, risk and prevention. Gut vol. 61, (2) 311-318.

Houston Y, Lindsay JO, Jenkins H, McCartney S, Ahmad T, Arnott I, Croft N, Russell R et al.(2012). Perspectives of transition care in inflammatory bowel disease: A survey. Gastrointestinal Nursing vol. 10, (1) 30-35.

Goodhand J, Hedin CR, Croft NM, Lindsay JO(2011). Adolescents with IBD: the importance of structured transition care. J Crohns Colitis vol. 5, (6) 509-519.

Benton B, Norton C, Lindsay J, Dolan S, Andreyev HJN(2011). Can Nurses Manage Gastrointestinal Symptoms Arising from Pelvic Radiation Disease?. CLIN ONCOL-UK vol. 23, (8) 538-551.

Ng SC, Benjamin JL, McCarthy NE, Hedin CRH, Koutsoumpas A, Plamondon S, Price CL, Hart AL et al.(2011). Relationship between human intestinal dendritic cells, gut microbiota, and disease activity in Crohn's disease. Inflamm Bowel Dis vol. 17, (10) 2027-2037.

Benjamin JL, Hedin CRH, Koutsoumpas A, Ng SC, McCarthy NE, Hart AL, Kamm MA, Sanderson JD et al.(2011). Randomised, double-blind, placebo-controlled trial of fructo-oligosaccharides in active Crohn's disease. Gut vol. 60, (7) 923-929.

Duncan J, Sastrillo M, Baker J, Younge L, Anderson S, Lindsay J, Sanderson J, Irving P (2011). AN AUDIT OF ADHERENCE TO ANTI-TNF THERAPY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE. GUT. vol. 60,

Lindsay JO, Bloom S, Hamlin PJ, Hayward C, Percival F, Bean K, Bodger K (2011). AN EVALUATION OF THE IMPACT OF BIOLOGIC THERAPY ON SECONDARY CARE RESOURCE USE ASSOCIATED WITH THE MANAGEMENT OF CROHN'S DISEASE IN THE UK. GUT. vol. 60,

Hedin CR, McCarthy NE, Bhattacharjee S, James G, Whelan K, Lindsay JO, Stagg AJ (2011). V Delta 2+T CELL EXPANSION IN CROHN'S DISEASE: IMPACT OF INFLAMMATION, DISEASE ACTIVITY AND TREATMENT. GUT. vol. 60,

Steel AW, Mela CM, Lindsay JO, Gazzard BG, Goodier MR(2011). Increased proportion of CD16(+) NK cells in the colonic lamina propria of inflammatory bowel disease patients, but not after azathioprine treatment. Aliment Pharmacol Ther vol. 33, (1) 115-126.

Ng SC, Benjamin JL, McCarthy NE, Hedin CR, Koutsoumpas A, Plamondon S, Price CL, Hart AL et al. (2010). Relationship between human intestinal dendritic cells, gut microbiota, and disease activity in Crohn's disease. Inflamm Bowel Dis.

McCarthy NE, Hedin CRH, Bhattacharjee S, James GS, Whelan K, Lindsay JO, Stagg AJ (2010). Circulating 'gut-tropic' V delta 2 T-cells are expanded in some Crohn's disease patients and their siblings but are ablated by azathioprine therapy. IMMUNOLOGY. vol. 131, 107-107.

Sanders T, McCarthy N, Gellatly N, Lindsay J, Stagg A (2010). Factors from inflamed human intestinal mucosa act on dendritic cells to uncouple the imprinting of gut tropism from FoxP(3)(+) T cell generation. IMMUNOLOGY. vol. 131, 30-31.

Sanders T, McCarthy N, Gellatly N, Lindsay J, Stagg A (2010). Factors from inflamed human intestinal mucosa act on dendritic cells to uncouple the imprinting of gut tropism from FoxP3(+) T cell generation. IMMUNOLOGY. vol. 131, 134-135.

Hedin CRH, Mullard M, Sharratt E, Jansen C, Sanderson JD, Shirlaw P, Howe LC, Djemal S et al.(2010). Probiotic and prebiotic use in patients with inflammatory bowel disease: a case-control study. Inflamm Bowel Dis vol. 16, (12) 2099-2108.

Gellatly NL, Sanders TJ, Ahmed M, Mughal S, McCarthy NE, Pattni G, Lindsay JO, Stagg AJ (2010). Retinoic acid and aryl hydrocarbon receptor signalling: opposing effects on human dendritic cell differentiation and ability to imprint gut homing. IMMUNOLOGY. vol. 131, 155-155.

Vossenkämper A, Marchès O, Fairclough PD, Warnes G, Stagg AJ, Lindsay JO, Evans PC, Luong LA et al.(2010). Inhibition of NF-κB signaling in human dendritic cells by the enteropathogenic Escherichia coli effector protein NleE. J Immunol vol. 185, (7) 4118-4127.

Goodhand J, Dawson R, Hefferon M, Tshuma N, Swanson G, Wahed M, Croft NM, Lindsay JO(2010). Inflammatory bowel disease in young people: the case for transitional clinics. Inflamm Bowel Dis vol. 16, (6) 947-952.

Russo EA, O'Donnell S, Dearden J, Campbell S, Lindsay JO, O'Morain C, Orchard TR (2010). A RETROSPECTIVE SURVEY ON THE LONG-TERM EFFICACY OF THE SECOND BIOLOGIC IN THE MANAGEMENT OF CROHN'S DISEASE: RESULTS FROM A COMBINED ENGLISH IRISH COHORT. GUT. vol. 59, A64-A64.

Benjamin JL, Koutsoumpas A, Hedin CRH, Ng SC, Prescott NJ, Pessoa-Lopes P, Mathew CG, Kamm MA et al. (2010). DEMOGRAPHIC, CLINICAL AND GENETIC FACTORS ASSOCIATED WITH DYSBIOSIS IN PATIENTS WITH ACTIVE CROHN'S DISEASE. GUT. vol. 59, A5-A5.

Benjamin JL, Hedin CRH, Koutsoumpas A, Ng SC, Hart AL, Kamm MA, Sanderson JD, Knight SC et al. (2010). NO CLINICAL BENEFIT OF PREBIOTICS IN THE TREATMENT OF ACTIVE CROHN'S DISEASE: A DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED TRIAL. GUT. vol. 59, A1-A2.

Punekar YS, Sunderland T, Hawkins N, Lindsay J(2010). Cost-Effectiveness of Scheduled Maintenance Treatment with Infliximab for Pediatric Crohn's Disease. VALUE HEALTH vol. 13, (2) 188-195.

Russo EA, Iacucci M, Lindsay JO, Campbell S, Hart A, Hamlin J, Orchard T, Arebi N et al.(2010). Survey on the use of adalimumab as maintenance therapy in Crohn's disease in England and Ireland. EUR J GASTROEN HEPAT vol. 22, (3) 334-339.

Dignass A, Van Assche G, Lindsay JO, Lemann M, Soderholm J, Colombel JF, Danese S, D'Hoore A et al.(2010). The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. J CROHNS COLITIS vol. 4, (1) 28-62.

Van Assche G, Dignass A, Reinisch W, van der Woude CJ, Sturm A, De Vos M, Guslandi M, Oldenburg B et al.(2010). The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations. J CROHNS COLITIS vol. 4, (1) 63-101.

Sharma N, Lindsay J(2009). Anti-TNF-Alpha-Induced Psoriasis - An Unusual Paradox. Case Rep Gastroenterol vol. 3, (3) 404-407.

Wahed M, Louis-Auguste JR, Baxter LM, Limdi JK, McCartney SA, Lindsay JO, Bloom SL(2009). Efficacy of methotrexate in Crohn's disease and ulcerative colitis patients unresponsive or intolerant to azathioprine mercaptopurine. ALIMENT PHARM THER vol. 30, (6) 614-620.

Russo EA, Lindsay J, Campbell S, Hart AL, Hamlin PJ, Orchard TR, Arebi N, Nightingale J et al. (2009). EXPERIENCE ON THE USE OF ADALIMUMAB AS MAINTENANCE THERAPY IN CROHN'S DISEASE IN ENGLAND AND IRELAND. GUT. vol. 58, A61-A62.

Goodhand J, Tang J, Naik S, Croft NM, Lindsay JO (2009). INFLIXIMAB USE IN ADOLESCENTS WITH INFLAMMATORY BOWEL DISEASE. GUT. vol. 58, A63-A64.

Russo EA, Harris AW, Campbell S, Lindsay J, Hart A, Arebi N, Milestone A, Tsai HH et al.(2009). Experience of maintenance infliximab therapy for refractory ulcerative colitis from six centres in England. Aliment Pharmacol Ther vol. 29, (3) 308-314.

Ansari A, Arenas M, Greenfield SM, Morris D, Lindsay J, Gilshenan K, Smith M, Lewis C et al.(2008). Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of inflammatory bowel disease. ALIMENT PHARM THER vol. 28, (8) 973-983.

Lindsay J, Punekar YS, Morris J, Chung-Faye G(2008). Health-economic analysis: cost-effectiveness of scheduled maintenance treatment with infliximab for Crohn's disease--modelling outcomes in active luminal and fistulizing disease in adults. Aliment Pharmacol Ther vol. 28, (1) 76-87.

Wahed M, Louis-Auguste JR, Baxter LM, Limdi JK, Lindsay JO, McCartney S, Bloom SL(2008). Efficacy of methotrexate in Crohns disease patients previously on thiopurine therapy. GASTROENTEROLOGY vol. 134, (4) A661-A661.

Wahed M, Louis-Auguste JR, Baxter LM, Limdi JK, McCartney S, Bloom SL, Lindsay JO(2008). Efficacy of methotrexate in ulcerative colitis. GASTROENTEROLOGY vol. 134, (4) A662-A662.

Russo E, Harris A, Campbell S, Lindsay JO, Hart AL, Arebi N, Milestone A, Tsai HH et al.(2008). Experience of maintenance infliximab therapy for refractory ulcerative colitis in England. GASTROENTEROLOGY vol. 134, (4) A657-A657.

Dawson R, Hefferon M, Croft N, Lindsay JO(2008). IBD in adolescents: A case control study of disease extent and therapeutic strategy. GASTROENTEROLOGY vol. 134, (4) A506-A506.

Lindsay JO, Punekar Y, Morris J, Chung-Faye G (2008). Is scheduled maintenance treatment with infliximab cost effective in patients with Crohn's disease?. GASTROINTESTINAL ENDOSCOPY. vol. 67, AB318-AB318.

Ng SC, Koutsoumpas A, Hedin CR, McCarthy NE, Plamondon S, Kamm MA, Knight SC, Forbes A et al. (2008). Production of IL-10 by colonic dendritic cells is associated with higher concentrations of faecal microbiota in patients with active Crohn's disease. GASTROENTEROLOGY. vol. 134, A653-A654.

Koutsoumpas A, Hedin CR, Ng SC, Kamm MA, Sanderson JD, Knight SC, Stagg AJ, Forbes A et al.(2008). The concentration and proportion of key bacterial groups of the faecal microbiota are different between smokers and non-smokers with active Crohn's disease. GASTROENTEROLOGY vol. 134, (4) A497-A497.

Wahed M, Louis-Auguste JR, Baxter LM, Limdi JK, Lindsay JO, McCartney SA, Bloom SL (2008). Efficacy of methotrexate in crohn's disease patients previously on thiopurine therapy. GUT. vol. 57, A152-A152.

Wahed M, Louis-Auguste JR, Baxter LM, Limdi JK, McCartney SA, Bloom SL, Lindsay JO (2008). Efficacy of methotrexate in ulcerative colitis. GUT. vol. 57, A152-A152.

Hedin CRH, Koutsoumpas A, Forbes A, Sanderson J, Stagg AJ, Knight SC, Whelan K, Lindsay JO (2008). Factors that limit recruitment to clinical trials in crohn's disease. GUT. vol. 57, A118-A118.

Ng SC, Koutsoumpas A, Hedin CR, McCarthy NE, Plamondon S, Kamm MA, Knight SC, Forbes A et al. (2008). Production of il-10 by colonic dendritic cells is associated with higher concentrations of faecal microbiota in patients with active crohn's disease. GUT. vol. 57, A144-A144.

Koutsoumpas A, Hedin CRH, Ng SC, Kamm MA, Sanderson JD, Knight SC, Stagg AJ, Forbes A et al. (2008). Smokers with active crohn's disease have differences in the concentration and proportion of key bacterial groups of the faecal microbiota. GUT. vol. 57, A152-A153.

D'Souza R, Lindsay J(2007). Biologic Treatments in IBD. Clinical Dilemmas in Inflammatory Bowel Disease,

Mela CM, Steel A, Lindsay J, Gazzard BG, Gotch FM, Goodier MR(2007). Depletion of natural killer cells in the colonic lamina propria of viraemic HIV-1-infected individuals. AIDS vol. 21, (16) 2177-2182.

Hedin C, Whelan K, Lindsay JO (2007). Evidence for the use of probiotics and prebiotics in inflammatory bowel disease: a review of clinical trials. Proc Nutr Soc. vol. 66, 307-315.

Wood E, Lindsay JO (2007). Trainee colonoscopy audit: North East Thames. GUT. vol. 56, A104-A104.

Hirri HM, Green PJ, Lindsay J(2006). Von Willebrand's disease and angiodysplasia treated with thalidomide. Haemophilia vol. 12, (3) 285-286.

Parkes G, Fairclough P, Lindsay JO (2006). Endoscopy in high risk cardiovascular patients. GUT. vol. 55, A56-A56.

Lindsay JO, Whelan K, Stagg AJ, Gobin P, Al-Hassi HO, Rayment N, Kamm MA, Knight SC et al.(2006). Clinical, microbiological, and immunological effects of fructo-oligosaccharide in patients with Crohn's disease. Gut vol. 55, (3) 348-355.

Lindsay J (2006). Medical management of diverticular disease: the role of bulking agents. Diverticular Disease: Emerging Evidence in a Common Condition. Editors: Kruis, W, Forbes, A, Jauch, KW, Kreis, ME et al., vol. 148, 155-160.

Al-Hassi HO, Lindsay JO, Whelan K, Gobin P, Forbes A, Kamm MA, Knight SC, Stagg AJ(2005). Modulation of intestinal dendritic cells (DC) in Crohn's disease patients taking a fructo-oligosaccharide prebiotic. IMMUNOLOGY vol. 116, 4-4.

Mawdsley JED, Lindsay J, Rampton D(2005). Synbiotic therapy for ulcerative colitis. GUT vol. 54, (9) 1346-1346.

Lindsay JO, Whelan K, Stagg A, Gobin P, Omar H, Kamm MA, Knight SC, Forbes A (2005). Prebiotic fructo-oligosaccharide as a therapy for Crohn's disease: An open label trial. GUT. vol. 54, A23-A24.

Lindsay JO, Sandison A, Cohen P, Brennan FM, Hodgson HJF(2004). IL-10 gene therapy is therapeutic for dextran sodium sulfate-induced murine colitis. Dig Dis Sci vol. 49, (7-8) 1327-1334.

Lindsay JO(2004). Local delivery of adenoviral vectors encoding murine interleukin 10 induces colonic interleukin 10 production and is therapeutic for murine colitis (Retraction of vol 52, pg 981, 2003). GUT vol. 53, (5) 774-774.

Lindsay JO, Andreyev HJN, Vlavianos P, Westaby D(2004). Self-expanding metal stents for the palliation of malignant gastroduodenal obstruction in patients unsuitable for surgical bypass. Aliment Pharmacol Ther vol. 19, (8) 901-905.

Ansari A, Arenas M, Lindsay J, Morris D, Greenfield S, Raoof S, Fong F, Fairbanks L et al. (2004). Pharmacogenetic profiling in azathioprine treatment: TPMT, ITPA, and MTHFR polymorphisms and toxicity. GUT. vol. 53, A105-A105.

Ansari A, Arenas M, Lindsay J, Morris D, Greenfield S, Soon SL, Fairbanks S, Duley J et al. (2004). Prospective study of thioguanine nucleotide measurement during azathioprine treatment for inflammatory bowel disease. GUT. vol. 53, A105-A105.

Lindsay JO, Ciesielski CJ, Scheinin T, Brennan FM, Hodgson HJ(2003). Local delivery of adenoviral vectors encoding murine interleukin 10 induces colonic interleukin 10 production and is therapeutic for murine colitis. Gut vol. 52, (7) 981-987.

Lindsay JO, Vlavianos P, Andreyev HJN, Westaby D (2003). Enteral stents for the palliation of malignant gastric and duodenal obstruction. GUT. vol. 52, A72-A72.

Lindsay JO, Ciesielski CJ, Scheinin T, Brennan FM, Hodgson HJ(2003). Local delivery of adenoviral vectors encoding murine interleukin 10 induces colonic interleukin 10 production and is therapeutic for murine colitis. Gut vol. 52, (3) 363-369.

Lindsay J, Van Montfrans C, Brennan F, Van Deventer S, Drillenburg P, Hodgson H, Te Velde A, Sol Rodriguez Pena M(2002). IL-10 gene therapy prevents TNBS-induced colitis. Gene Ther vol. 9, (24) 1715-1721.

Lindsay JO, van Montfrans C, te Velde AA, Brennan FM, Hodgson HJF, Pena MSR(2002). IL-10 gene therapy ameliorates TNBS induced colitis. GUT vol. 50, A14-A14.

Lindsay JO, Ciesielski CJ, Scheinin T, Brennan F, Hodgson HJF(2002). Local IL-10 gene therapy induces colonic IL-10 release and is therapeutic for murine colitis. GUT vol. 50, A30-A30.

Lindsay JO(2002). Interleukin-10 gene therapy: A cure for Crohn's disease?. CME Journal Gastroenterology, Hepatology and Nutrition vol. 5, (1) 11-14.

Lindsay JO, Hodgson HJ(2001). Review article: the immunoregulatory cytokine interleukin-10--a therapy for Crohn's disease?. Aliment Pharmacol Ther vol. 15, (11) 1709-1716.

Lindsay JO, Ciesielski CJ, Scheinin T, Hodgson HJ, Brennan FM(2001). The prevention and treatment of murine colitis using gene therapy with adenoviral vectors encoding IL-10. J Immunol vol. 166, (12) 7625-7633.

LINDSAY JO, Brennan FM, Hodgson HJF, Scheinin T, Ciesielski CJ(2001). The prevention and treatment of murine colitis using adenoviral vectors encoding interleukin-10. Journal of Immunology vol. 166, 7625-7633.

Lindsay JO, Ciesielski CJ, Brennan FM, Hodgson HJ(2001). Rectal administration of an adenoviral vector encoding IL-10 induces colonic IL-10 release with minimal anti-adenoviral response. GASTROENTEROLOGY vol. 120, (5) A687-A688.

Lindsay JO, Ciesielski CJ, Scheinin T, Brennan FM, Hodgson HJ(2001). The prevention and treatment of murine colitis using gene therapy with adenoviral vectors encoding interleukin-10. GASTROENTEROLOGY vol. 120, (5) A686-A686.

Lindsay JO, Ciesielski CJ, Scheinin T, Brennan F, Hodgson HJF(2001). The prevention and treatment of murine colitis using gene therapy with adenoviral vectors encoding interleukin-10. GUT vol. 48, A109-A109.